Achievements, challenges and unmet needs for haemophilia patients with inhibitors

Y. Dargaud, A. Pavlova, S. Lacroix-Desmazes, K. Fischer, M. Soucie, S. Claeyssens, D. W. Scott, R. d'Oiron, G. Lavigne-Lissalde, G. Kenet, C. Escuriola Ettingshausen, A. Borel-Derlon, T. Lambert, G. Pasta, C. Négrier

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Over the past 20 years, there have been many advances in haemophilia treatment that have allowed patients to take greater control of their disease. However, the development of factor VIII (FVIII) inhibitors is the greatest complication of the disease and a challenge in the treatment of haemophilia making management of bleeding episodes difficult and surgical procedures very challenging. A meeting to discuss the unmet needs of haemophilia patients with inhibitors was held in Paris on 20 November 2014. Topics discussed were genetic and non-genetic risk factors for the development of inhibitors, immunological aspects of inhibitor development, FVIII products and inhibitor development, generation and functional properties of engineered antigen-specific T regulatory cells, suppression of immune responses to FVIII, prophylaxis in haemophilia patients with inhibitors, epitope mapping of FVIII inhibitors, current controversies in immune tolerance induction therapy, surgery in haemophilia patients with inhibitors and future perspectives for the treatment of haemophilia patients with inhibitors. A summary of the key points discussed is presented in this paper.

Original languageEnglish
Pages (from-to)1-24
Number of pages24
JournalHaemophilia
Volume22
DOIs
Publication statusPublished - Jan 1 2016

Fingerprint

Hemophilia A
Factor VIII
Epitope Mapping
Immune Tolerance
Paris
Regulatory T-Lymphocytes
Therapeutics
Hemorrhage
Antigens

Keywords

  • FVIII products
  • Genetics
  • Haemophilia
  • Inhibitors
  • Prophylaxis
  • Surgery

ASJC Scopus subject areas

  • Hematology
  • Genetics(clinical)

Cite this

Dargaud, Y., Pavlova, A., Lacroix-Desmazes, S., Fischer, K., Soucie, M., Claeyssens, S., ... Négrier, C. (2016). Achievements, challenges and unmet needs for haemophilia patients with inhibitors. Haemophilia, 22, 1-24. https://doi.org/10.1111/hae.12860

Achievements, challenges and unmet needs for haemophilia patients with inhibitors. / Dargaud, Y.; Pavlova, A.; Lacroix-Desmazes, S.; Fischer, K.; Soucie, M.; Claeyssens, S.; Scott, D. W.; d'Oiron, R.; Lavigne-Lissalde, G.; Kenet, G.; Escuriola Ettingshausen, C.; Borel-Derlon, A.; Lambert, T.; Pasta, G.; Négrier, C.

In: Haemophilia, Vol. 22, 01.01.2016, p. 1-24.

Research output: Contribution to journalArticle

Dargaud, Y, Pavlova, A, Lacroix-Desmazes, S, Fischer, K, Soucie, M, Claeyssens, S, Scott, DW, d'Oiron, R, Lavigne-Lissalde, G, Kenet, G, Escuriola Ettingshausen, C, Borel-Derlon, A, Lambert, T, Pasta, G & Négrier, C 2016, 'Achievements, challenges and unmet needs for haemophilia patients with inhibitors', Haemophilia, vol. 22, pp. 1-24. https://doi.org/10.1111/hae.12860
Dargaud Y, Pavlova A, Lacroix-Desmazes S, Fischer K, Soucie M, Claeyssens S et al. Achievements, challenges and unmet needs for haemophilia patients with inhibitors. Haemophilia. 2016 Jan 1;22:1-24. https://doi.org/10.1111/hae.12860
Dargaud, Y. ; Pavlova, A. ; Lacroix-Desmazes, S. ; Fischer, K. ; Soucie, M. ; Claeyssens, S. ; Scott, D. W. ; d'Oiron, R. ; Lavigne-Lissalde, G. ; Kenet, G. ; Escuriola Ettingshausen, C. ; Borel-Derlon, A. ; Lambert, T. ; Pasta, G. ; Négrier, C. / Achievements, challenges and unmet needs for haemophilia patients with inhibitors. In: Haemophilia. 2016 ; Vol. 22. pp. 1-24.
@article{52d1eeba321a4d6a9b6d96dd8e6bfa1a,
title = "Achievements, challenges and unmet needs for haemophilia patients with inhibitors",
abstract = "Over the past 20 years, there have been many advances in haemophilia treatment that have allowed patients to take greater control of their disease. However, the development of factor VIII (FVIII) inhibitors is the greatest complication of the disease and a challenge in the treatment of haemophilia making management of bleeding episodes difficult and surgical procedures very challenging. A meeting to discuss the unmet needs of haemophilia patients with inhibitors was held in Paris on 20 November 2014. Topics discussed were genetic and non-genetic risk factors for the development of inhibitors, immunological aspects of inhibitor development, FVIII products and inhibitor development, generation and functional properties of engineered antigen-specific T regulatory cells, suppression of immune responses to FVIII, prophylaxis in haemophilia patients with inhibitors, epitope mapping of FVIII inhibitors, current controversies in immune tolerance induction therapy, surgery in haemophilia patients with inhibitors and future perspectives for the treatment of haemophilia patients with inhibitors. A summary of the key points discussed is presented in this paper.",
keywords = "FVIII products, Genetics, Haemophilia, Inhibitors, Prophylaxis, Surgery",
author = "Y. Dargaud and A. Pavlova and S. Lacroix-Desmazes and K. Fischer and M. Soucie and S. Claeyssens and Scott, {D. W.} and R. d'Oiron and G. Lavigne-Lissalde and G. Kenet and {Escuriola Ettingshausen}, C. and A. Borel-Derlon and T. Lambert and G. Pasta and C. N{\'e}grier",
year = "2016",
month = "1",
day = "1",
doi = "10.1111/hae.12860",
language = "English",
volume = "22",
pages = "1--24",
journal = "Haemophilia",
issn = "1351-8216",
publisher = "Wiley-Blackwell Publishing Ltd",

}

TY - JOUR

T1 - Achievements, challenges and unmet needs for haemophilia patients with inhibitors

AU - Dargaud, Y.

AU - Pavlova, A.

AU - Lacroix-Desmazes, S.

AU - Fischer, K.

AU - Soucie, M.

AU - Claeyssens, S.

AU - Scott, D. W.

AU - d'Oiron, R.

AU - Lavigne-Lissalde, G.

AU - Kenet, G.

AU - Escuriola Ettingshausen, C.

AU - Borel-Derlon, A.

AU - Lambert, T.

AU - Pasta, G.

AU - Négrier, C.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Over the past 20 years, there have been many advances in haemophilia treatment that have allowed patients to take greater control of their disease. However, the development of factor VIII (FVIII) inhibitors is the greatest complication of the disease and a challenge in the treatment of haemophilia making management of bleeding episodes difficult and surgical procedures very challenging. A meeting to discuss the unmet needs of haemophilia patients with inhibitors was held in Paris on 20 November 2014. Topics discussed were genetic and non-genetic risk factors for the development of inhibitors, immunological aspects of inhibitor development, FVIII products and inhibitor development, generation and functional properties of engineered antigen-specific T regulatory cells, suppression of immune responses to FVIII, prophylaxis in haemophilia patients with inhibitors, epitope mapping of FVIII inhibitors, current controversies in immune tolerance induction therapy, surgery in haemophilia patients with inhibitors and future perspectives for the treatment of haemophilia patients with inhibitors. A summary of the key points discussed is presented in this paper.

AB - Over the past 20 years, there have been many advances in haemophilia treatment that have allowed patients to take greater control of their disease. However, the development of factor VIII (FVIII) inhibitors is the greatest complication of the disease and a challenge in the treatment of haemophilia making management of bleeding episodes difficult and surgical procedures very challenging. A meeting to discuss the unmet needs of haemophilia patients with inhibitors was held in Paris on 20 November 2014. Topics discussed were genetic and non-genetic risk factors for the development of inhibitors, immunological aspects of inhibitor development, FVIII products and inhibitor development, generation and functional properties of engineered antigen-specific T regulatory cells, suppression of immune responses to FVIII, prophylaxis in haemophilia patients with inhibitors, epitope mapping of FVIII inhibitors, current controversies in immune tolerance induction therapy, surgery in haemophilia patients with inhibitors and future perspectives for the treatment of haemophilia patients with inhibitors. A summary of the key points discussed is presented in this paper.

KW - FVIII products

KW - Genetics

KW - Haemophilia

KW - Inhibitors

KW - Prophylaxis

KW - Surgery

UR - http://www.scopus.com/inward/record.url?scp=84953725784&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84953725784&partnerID=8YFLogxK

U2 - 10.1111/hae.12860

DO - 10.1111/hae.12860

M3 - Article

AN - SCOPUS:84953725784

VL - 22

SP - 1

EP - 24

JO - Haemophilia

JF - Haemophilia

SN - 1351-8216

ER -